Core Viewpoint - Junsheng Tai Pharmaceutical-B (2511.HK) continues its upward trend, reaching a new high since mid-June 2024, with a significant increase in market value and a notable reduction in losses compared to the previous year [1] Financial Performance - In the first half of 2025, the company reported a loss of 113.9 million HKD, a substantial improvement from a loss of 210.9 million HKD in the same period of 2024 [1] Product Pipeline - The company's core product, HTD1801, is a globally innovative oral anti-inflammatory and metabolic regulator targeting the gut-liver system, currently under development for various CKM-related diseases [1] - HTD1801 is being developed for the treatment of Type 2 Diabetes Mellitus (T2DM), Metabolic Associated Fatty Liver Disease (MASH), Chronic Kidney Disease (CKD), Obesity, Primary Sclerosing Cholangitis (PSC), and Severe Hypertriglyceridemia (SHTG) [1] - In addition to HTD1801, the company has a strong pipeline of innovative drug candidates, including HTD4010, HTF1037, HTF1057, HTD1804, HTD1805, and HTD2802, targeting a total of ten potential indications [1]
港股异动丨君圣泰医药-B盘中大涨超15%，录得3连升，创2024年6月中旬以来新高